Janssen and Fate Collaborate to Develop iPSC-derived CAR-T and NK Therapies
On Thursday, April 2, Fate Therapeutics announced a multi-year collaboration with Janssen to develop and commercialize new off-the-shelf CAR-NK and CAR-T cell products derived from induced pluripotent stem cells (iPSCs). As part of the agreement, Fate will apply its iPSC product platform and Janssen will contribute proprietary antigen-binding domains for up to four tumor-associated antigen targets. Below, FENIX provides highlights from the deal and analysis of how Janssen’s ability to develop off-the-shelf cell therapies, potentially also targeting solid tumors, could strengthen the company’s position in the cell therapy field.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.